Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 539

1.

Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors.

Sainas S, Pippione AC, Lupino E, Giorgis M, Circosta P, Gaidano V, Goyal P, Bonanni D, Rolando B, Cignetti A, Ducime A, Andersson M, Järvå M, Friemann R, Piccinini M, Ramondetti C, Buccinnà B, Al-Karadaghi S, Boschi D, Saglio G, Lolli ML.

J Med Chem. 2018 Jul 9. doi: 10.1021/acs.jmedchem.8b00373. [Epub ahead of print]

PMID:
29939742
2.

Present results and future perspectives in optimizing chronic myeloid leukemia therapy.

Carella AM, Saglio G, Mahon XF, Mauro MJ.

Haematologica. 2018 Jun;103(6):928-930. doi: 10.3324/haematol.2017.182022. No abstract available.

3.

Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective.

Saglio G, Sharf G, Almeida A, Bogdanovic A, Bombaci F, Čugurović J, Deekes N, Garcia-Gutiérrez V, de Jong J, Narbutas Š, Westerweel P, Zackova D.

Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):375-379. doi: 10.1016/j.clml.2018.04.005. Epub 2018 Apr 25. Review.

4.

Expressional changes in stemness markers post electrochemotherapy in pancreatic cancer cells.

Ali MS, Gill KS, Saglio G, Cilloni D, Soden DM, Forde PF.

Bioelectrochemistry. 2018 Aug;122:84-92. doi: 10.1016/j.bioelechem.2018.03.009. Epub 2018 Mar 15.

PMID:
29574322
5.

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.

Ross DM, Masszi T, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E, Garcia-Gutierrez V, Gattermann N, le Coutre PD, Martino B, Saussele S, Giles FJ, Radich JP, Saglio G, Deng W, Krunic N, Bédoucha V, Gopalakrishna P, Hochhaus A.

J Cancer Res Clin Oncol. 2018 May;144(5):945-954. doi: 10.1007/s00432-018-2604-x. Epub 2018 Feb 22.

6.

Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.

Mughal TI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ, Cortes JE, Barbui T, Hehlmann R, Mauro M, Saussele S, Radich JP, Van Etten RA, Saglio G, Verstovek S, Gale RP, Abdel-Wahab O.

Leuk Res. 2018 Apr;67:67-74. doi: 10.1016/j.leukres.2018.02.008. Epub 2018 Feb 14. Review.

PMID:
29466766
7.

Prognostic significance of The Wilms' Tumor-1 (WT1) rs16754 polymorphism in acute myeloid leukemia.

Petiti J, Rosso V, Lo Iacono M, Calabrese C, Signorino E, Gaidano V, Berger M, Saglio G, Cilloni D.

Leuk Res. 2018 Apr;67:6-11. doi: 10.1016/j.leukres.2018.01.016. Epub 2018 Feb 5.

PMID:
29407184
8.

Dasatinib dose management for the treatment of chronic myeloid leukemia.

Talpaz M, Saglio G, Atallah E, Rousselot P.

Cancer. 2018 Apr 15;124(8):1660-1672. doi: 10.1002/cncr.31232. Epub 2018 Jan 25. Review.

9.

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.

Galimberti S, Bucelli C, Arrigoni E, Baratè C, Grassi S, Ricci F, Guerrini F, Ciabatti E, Fava C, D'Avolio A, Fontanelli G, Cambrin GR, Isidori A, Loscocco F, Caocci G, Greco M, Bocchia M, Aprile L, Gozzini A, Scappini B, Cattaneo D, Scortechini AR, La Nasa G, Bosi A, Leoni P, Danesi R, Saglio G, Visani G, Cortelezzi A, Petrini M, Iurlo A, Di Paolo A.

Oncotarget. 2017 Sep 30;8(50):88021-88033. doi: 10.18632/oncotarget.21406. eCollection 2017 Oct 20.

10.

First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.

Saglio G, Jabbour E.

Leuk Lymphoma. 2018 Jul;59(7):1523-1538. doi: 10.1080/10428194.2017.1379074. Epub 2017 Oct 3.

PMID:
28972424
11.

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.

Iurlo A, Galimberti S, Abruzzese E, Annunziata M, Bonifacio M, Latagliata R, Pregno P, Ferrero D, Sorà F, Orlandi EM, Fava C, Cattaneo D, Bucelli C, Binotto G, Pungolino E, Tiribelli M, Gozzini A, Gugliotta G, Castagnetti F, Stagno F, Rege-Cambrin G, Martino B, Luciano L, Breccia M, Sica S, Bocchia M, Pane F, Saglio G, Rosti G, Specchia G, Cortelezzi A, Baccarani M.

Ann Hematol. 2018 Jan;97(1):95-100. doi: 10.1007/s00277-017-3144-1. Epub 2017 Oct 2.

PMID:
28971265
12.

CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report.

Dogliotti I, Fava C, Serra A, Gottardi E, Daraio F, Carnuccio F, Giugliano E, Bocchia M, Saglio G, Rege-Cambrin G.

Stem Cell Investig. 2017 Jun 23;4:57. doi: 10.21037/sci.2017.06.02. eCollection 2017.

13.

Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia Patients.

Casnici C, Crotta K, Volpe G, Panuzzo C, Lattuada D, Mesiano G, Saglio G, Marelli O.

Monoclon Antib Immunodiagn Immunother. 2017 Aug;36(4):149-156. doi: 10.1089/mab.2016.0054. Epub 2017 Jul 13.

PMID:
28704165
14.

Chronic myeloid leukemia: room for improvement?

Baccarani M, Pane F, Rosti G, Russo D, Saglio G.

Haematologica. 2017 Jul;102(7):1131-1133. doi: 10.3324/haematol.2017.166280. No abstract available.

15.

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.

Santini V, Allione B, Zini G, Gioia D, Lunghi M, Poloni A, Cilloni D, Sanna A, Masiera E, Ceccarelli M, Abdel-Wahab O, Terenzi A, Angelucci E, Finelli C, Onida F, Pelizzari A, Ferrero D, Saglio G, Figueroa M, Levis A.

Leukemia. 2018 Feb;32(2):413-418. doi: 10.1038/leu.2017.186. Epub 2017 Jun 13.

16.

The biology of CML supports second-generation TKIs as frontline treatment.

Fava C, Saglio G.

Clin Adv Hematol Oncol. 2017 Apr;15(4):302-307. No abstract available.

PMID:
28591106
17.

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia.

Gugliotta G, Castagnetti F, Breccia M, Albano F, Iurlo A, Intermesoli T, Abruzzese E, Levato L, D'Adda M, Pregno P, Cavazzini F, Stagno F, Martino B, La Barba G, Sorà F, Tiribelli M, Bigazzi C, Binotto G, Bonifacio M, Caracciolo C, Soverini S, Foà R, Cavo M, Martinelli G, Pane F, Saglio G, Baccarani M, Rosti G; Gruppo Italiano Malattie Ematologiche dell’Adulto - Chronic Myeloid Leukemia Working Party.

Haematologica. 2017 Sep;102(9):1530-1536. doi: 10.3324/haematol.2017.169532. Epub 2017 Jun 1.

18.

Altered Erythropoiesis in Mouse Models of Type 3 Hemochromatosis.

Pellegrino RM, Riondato F, Ferbo L, Boero M, Palmieri A, Osella L, Pollicino P, Miniscalco B, Saglio G, Roetto A.

Biomed Res Int. 2017;2017:2408941. doi: 10.1155/2017/2408941. Epub 2017 May 2.

19.

Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.

Saglio G, le Coutre P, Cortes J, Mayer J, Rowlings P, Mahon FX, Kroog G, Gooden K, Subar M, Shah NP.

Ann Hematol. 2017 Aug;96(8):1303-1313. doi: 10.1007/s00277-017-3012-z. Epub 2017 May 22.

20.

Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study.

Messa E, Biale L, Castiglione A, Lunghi M, Bonferroni M, Salvi F, Allione B, Ferrero D, Calabrese C, De Gobbi M, Nicoli P, Gioia D, Levis A, Saglio G, Cilloni D.

Leuk Lymphoma. 2017 Nov;58(11):2752-2754. doi: 10.1080/10428194.2017.1312385. Epub 2017 May 9. No abstract available.

PMID:
28482720
21.

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.

Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G; GIMEMA CML Working Party.

Am J Hematol. 2017 Aug;92(8):797-805. doi: 10.1002/ajh.24774. Epub 2017 May 30.

PMID:
28466557
22.

Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.

Carrà G, Panuzzo C, Torti D, Parvis G, Crivellaro S, Familiari U, Volante M, Morena D, Lingua MF, Brancaccio M, Guerrasio A, Pandolfi PP, Saglio G, Taulli R, Morotti A.

Oncotarget. 2017 May 30;8(22):35508-35522. doi: 10.18632/oncotarget.16348.

23.

Epha3 acts as proangiogenic factor in multiple myeloma.

Caivano A, La Rocca F, Laurenzana I, Annese T, Tamma R, Famigliari U, Simeon V, Trino S, De Luca L, Villani O, Berardi S, Basile A, Vacca A, Saglio G, Del Vecchio L, Musto P, Cilloni D.

Oncotarget. 2017 May 23;8(21):34298-34309. doi: 10.18632/oncotarget.16100.

24.

IκB-α: At the crossroad between oncogenic and tumor-suppressive signals.

Morotti A, Crivellaro S, Panuzzo C, Carrà G, Guerrasio A, Saglio G.

Oncol Lett. 2017 Feb;13(2):531-534. doi: 10.3892/ol.2016.5465. Epub 2016 Dec 6.

25.

Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.

Galeotti L, Ceccherini F, Domingo D, Laurino M, Polillo M, Di Paolo A, Baratè C, Fava C, D'Avolio A, Cervetti G, Guerrini F, Fontanelli G, Ciabatti E, Grassi S, Arrigoni E, Danesi R, Petrini M, Cornolti F, Saglio G, Galimberti S.

Cancer Chemother Pharmacol. 2017 Apr;79(4):767-773. doi: 10.1007/s00280-017-3271-3. Epub 2017 Mar 13.

PMID:
28289867
26.

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.

Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E, García-Gutiérrez V, Gattermann N, Wiktor-Jedrzejczak W, le Coutre PD, Martino B, Saussele S, Menssen HD, Deng W, Krunic N, Bedoucha V, Saglio G.

Leukemia. 2017 Jul;31(7):1525-1531. doi: 10.1038/leu.2017.63. Epub 2017 Feb 20.

27.

Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Sertić J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP.

PLoS One. 2017 Feb 16;12(2):e0172595. doi: 10.1371/journal.pone.0172595. eCollection 2017.

28.

5'UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia.

Marconi C, Canobbio I, Bozzi V, Pippucci T, Simonetti G, Melazzini F, Angori S, Martinelli G, Saglio G, Torti M, Pastan I, Seri M, Pecci A.

J Hematol Oncol. 2017 Jan 18;10(1):18. doi: 10.1186/s13045-016-0382-y.

29.

A novel assay to detect calreticulin mutations in myeloproliferative neoplasms.

Rosso V, Petiti J, Bracco E, Pedrola R, Carnuccio F, Signorino E, Carturan S, Calabrese C, Bot-Sartor G, Ronconi M, Serra A, Saglio G, Frassoni F, Cilloni D.

Oncotarget. 2017 Jan 24;8(4):6399-6405. doi: 10.18632/oncotarget.14113.

30.

Mimicking the Acute Myeloid Leukemia Niche for Molecular Study and Drug Screening.

Houshmand M, Soleimani M, Atashi A, Saglio G, Abdollahi M, Nikougoftar Zarif M.

Tissue Eng Part C Methods. 2017 Feb;23(2):72-85. doi: 10.1089/ten.TEC.2016.0404. Epub 2017 Jan 13.

PMID:
28007011
31.

Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib.

Giona F, Saglio G, Santopietro M, Menna G, Putti MC, Micalizzi C, Iaria G, Santoro N, Ladogana S, Mura R, Burnelli R, Consarino C, Cosmi C, Moleti ML, Leszl A, Tucci F, Nanni M, Diverio D, Biondi A, Locatelli F, Foà R.

Br J Haematol. 2018 Mar;180(6):895-898. doi: 10.1111/bjh.14458. Epub 2016 Dec 16. No abstract available.

PMID:
27984633
32.

Mechanisms of p53 Functional De-Regulation: Role of the IκB-α/p53 Complex.

Carrà G, Crivellaro S, Taulli R, Guerrasio A, Saglio G, Morotti A.

Int J Mol Sci. 2016 Nov 29;17(12). pii: E1997. Review.

33.

The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia.

Carrà G, Panuzzo C, Crivellaro S, Morena D, Taulli R, Guerrasio A, Saglio G, Morotti A.

Oncol Lett. 2016 Nov;12(5):3123-3126. Epub 2016 Sep 1.

34.

Modeling myeloproliferative neoplasms: From mutations to mouse models and back again.

Morotti A, Rocca S, Carrà G, Saglio G, Brancaccio M.

Blood Rev. 2017 May;31(3):139-150. doi: 10.1016/j.blre.2016.11.004. Epub 2016 Nov 24. Review.

PMID:
27899218
35.

Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection.

Carturan S, Petiti J, Rosso V, Calabrese C, Signorino E, Bot-Sartor G, Nicoli P, Gallo D, Bracco E, Morotti A, Panuzzo C, Gottardi E, Frassoni F, Saglio G, Cilloni D.

Oncotarget. 2016 Nov 8;7(45):74082-74096. doi: 10.18632/oncotarget.12269.

36.

A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Setric J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP.

PLoS One. 2016 Sep 16;11(9):e0162866. doi: 10.1371/journal.pone.0162866. eCollection 2016. Erratum in: PLoS One. 2017 Feb 16;12 (2):e0172595.

37.

Characterization of human mitochondrial ferritin promoter: identification of transcription factors and evidences of epigenetic control.

Guaraldo M, Santambrogio P, Rovelli E, Di Savino A, Saglio G, Cittaro D, Roetto A, Levi S.

Sci Rep. 2016 Sep 14;6:33432. doi: 10.1038/srep33432.

38.

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.

Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A.

Oncotarget. 2016 Nov 29;7(48):80083-80090. doi: 10.18632/oncotarget.11657.

39.

The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias.

Carrà G, Torti D, Crivellaro S, Panuzzo C, Taulli R, Cilloni D, Guerrasio A, Saglio G, Morotti A.

Oncotarget. 2016 Oct 4;7(40):66287-66298. doi: 10.18632/oncotarget.11507. Review.

40.

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.

Soverini S, De Benedittis C, Castagnetti F, Gugliotta G, Mancini M, Bavaro L, Machova Polakova K, Linhartova J, Iurlo A, Russo D, Pane F, Saglio G, Rosti G, Cavo M, Baccarani M, Martinelli G.

BMC Cancer. 2016 Aug 2;16:572. doi: 10.1186/s12885-016-2635-0.

41.

Transferrin Receptor 2 Dependent Alterations of Brain Iron Metabolism Affect Anxiety Circuits in the Mouse.

Pellegrino RM, Boda E, Montarolo F, Boero M, Mezzanotte M, Saglio G, Buffo A, Roetto A.

Sci Rep. 2016 Aug 1;6:30725. doi: 10.1038/srep30725.

42.

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.

Castagnetti F, Breccia M, Gugliotta G, Martino B, D'Adda M, Stagno F, Carella AM, Avanzini P, Tiribelli M, Trabacchi E, Visani G, Gobbi M, Salvucci M, Levato L, Binotto G, Capalbo SF, Bochicchio MT, Soverini S, Cavo M, Martinelli G, Alimena G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.

Haematologica. 2016 Oct;101(10):1200-1207. Epub 2016 Jul 28.

43.

Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia.

Morotti A, Torti D, Carra G, Panuzzo C, Crivellaro S, Taulli R, Fava C, Guerrasio A, Saglio G.

Curr Drug Targets. 2017;18(4):389-395. doi: 10.2174/1389450117666160608120527. Review.

PMID:
27291926
44.

Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.

Mughal TI, Abdel-Wahab O, Rampal R, Mesa R, Koschmieder S, Levine R, Hehlmann R, Saglio G, Barbui T, Van Etten RA.

Leuk Lymphoma. 2016 Jul;57(7):1517-26. doi: 10.1080/10428194.2016.1185783. Epub 2016 May 31. Review.

PMID:
27240645
45.

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.

Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A.

J Clin Oncol. 2016 Jul 10;34(20):2333-40. doi: 10.1200/JCO.2015.64.8899. Epub 2016 May 23.

46.

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.

Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Hochhaus A, Saglio G.

Am J Hematol. 2016 Sep;91(9):869-74. doi: 10.1002/ajh.24423. Epub 2016 Jun 20.

47.

The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase.

Crivellaro S, Carrà G, Panuzzo C, Taulli R, Guerrasio A, Saglio G, Morotti A.

BMC Cancer. 2016 May 16;16:314. doi: 10.1186/s12885-016-2346-6. Review.

48.

The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy.

Gallo D, Nicoli P, Calabrese C, Gaidano V, Petiti J, Rosso V, Signorino E, Carturan S, Bot-Sartor G, Volpe G, Frassoni F, Saglio G, Cilloni D.

Cancer Med. 2016 Jul;5(7):1650-3. doi: 10.1002/cam4.735. Epub 2016 May 11.

49.

Chronic myeloid leukemia: reminiscences and dreams.

Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, Gambacorti-Passerini C, Saglio G, Cortes J, Daley GQ.

Haematologica. 2016 May;101(5):541-58. doi: 10.3324/haematol.2015.139337. Review.

50.

Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.

Fava C, Rege-Cambrin G, Dogliotti I, Gottardi E, Berchialla P, Di Gioacchino B, Crasto F, Lorenzatti R, Volpengo A, Daraio F, Fantino C, Saglio G.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S96-S100. doi: 10.1016/j.clml.2016.03.008. Epub 2016 Apr 1. Review.

PMID:
27131622

Supplemental Content

Loading ...
Support Center